KrisstinaLorraineGowinDO

PubMed

• Myeloproliferative Neoplasms: Contemporary Review and Molecular Landscape.
  Mahmud, M., Vasireddy, S., Gowin, K., Amaraneni, A.> ;International Journal of Molecular Sciences. 2023 Dec 12
• 4 citations
  Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.
  Jacinta Perram, David M Ross, Donal McLornan, Krisstina Gowin, Nicolas Kröger, Vikas Gupta, Clinton Lewis, Nico Gagelmann, Nada Hamad> ;American Journal of Hematology. 2022 Nov 1
• TIMING IS EVERYTHING: When IS the Time Right for Transplant in Myelofibrosis Therapy?
  Krisstina Gowin> ;Transplantation and Cellular Therapy. 2022 Apr 1
• 13 citations
  Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment.
  Krisstina Gowin, Sheri Skerget, Jonathan J Keats, Joseph Mikhael, Andrew J. Cowan> ;Leukemia Research. 2021 Aug 17
• 8 citations
  The SIMM study: Survey of integrative medicine in myeloproliferative neoplasms.
  Krisstina Gowin, Blake T. Langlais, Heidi E. Kosiorek, Amylou C. Dueck, Denise Millstine, Jennifer Huberty, Ryan Eckert, Ruben A. Mesa> ;Cancer Medicine. 2020 Nov 3
• 2 citations
  Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature.
  Hninyee Win, Krisstina Gowin> ;Clinical Case Reports. 2020 Sep 17
• 12 citations
  Understanding the Mechanisms of Diet and Outcomes in Colon, Prostate, and Breast Cancer; Malignant Gliomas; and Cancer Patients on Immunotherapy.
  Shivtaj Mann, Manreet Sidhu, Krisstina Gowin> ;Nutrients. 2020 Jul 26
• 54 citations
  Survival following allogeneic transplant in patients with myelofibrosis.
  , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Blood Advances. 2020 May 12
• 3 citations
  Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic C...
  Onyemaechi Okolo, Krisstina Gowin> ;Current Hematologic Malignancy Reports. 2019 Aug 1
• 44 citations
  Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research.
  Jennifer Huberty, Ryan Eckert, Amylou C. Dueck, Heidi E. Kosiorek, Linda Larkey, Krisstina Gowin, Ruben A. Mesa> ;BMC Complementary and Alternative Medicine. 2019 Jun 7
• 1 citations
  Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis.
  Kamal Menghrajani, Philip S. Boonstra, Jessica Mercer, Cecelia Perkins, Krisstina Gowin, Alissa Weber, Ruben A. Mesa, Jason Gotlib, Lixia Wang, Jack W. Singer, Moshe T...> ;Leukemia & Lymphoma. 2019 Mar 21
• 22 citations
  Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study:
  Jennifer Huberty, Ryan Eckert, Linda Larkey, Krisstina Gowin, Jules Mitchell, Ruben A. Mesa> ;Integrative Cancer Therapies. 2018 Oct 23
• Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics
  Vincent T. Ma, Philip S. Boonstra, Kamal Menghrajani, Cecelia Perkins, Krisstina Gowin, Ruben A. Mesa, Jason Gotlib, Moshe Talpaz> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 May 1
• 17 citations
  Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms Recommendations for Future Research
  Ryan Eckert, Jennifer Huberty, Krisstina Gowin, Ruben A. Mesa, Lisa A. Marks> ;Integrative Cancer Therapies. 2017 Dec 1
• 23 citations
  Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms.
  Jennifer Huberty, Ryan Eckert, Krisstina Gowin, Jules Mitchell, Amylou C. Dueck, Brenda Ginos, Linda Larkey, Ruben A. Mesa> ;Haematologica. 2017 Oct 1
• 34 citations
  Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.
  Krisstina L. Gowin, Heidi E. Kosiorek, Amylou C. Dueck, John Mascarenhas, Ronald Hoffman, Craig B. Reeder, John K. Camoriano, Raoul Tibes, Katherine Gano, Jeanne Palme...> ;Leukemia Research. 2017 Sep 1
• 24 citations
  Pegylated interferon alpha – 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial
  Krisstina L. Gowin, Tania Jain, Heidi E. Kosiorek, Raoul Tibes, John K. Camoriano, Jeanne Palmer, Ruben A. Mesa> ;Leukemia Research. 2017 Mar 1
• 21 citations
  Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis
  Krisstina L. Gowin, Maria Coakley, Heidi E. Kosiorek, Ruben A. Mesa> ;Haematologica. 2016 Oct 1
• 5 citations
  Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis.
  Krisstina L. Gowin, Srdan Verstovsek, Naval Daver, Naveen Pemmaraju, Ricardo Valdez, Heidi E. Kosiorek, Amylou C. Dueck, Ruben A. Mesa> ;Leukemia Research. 2015 Jul 1
• 7 citations
  Profile of pomalidomide and its potential in the treatment of myelofibrosis.
  Krisstina L. Gowin, Ruben A. Mesa> ;Therapeutics and Clinical Risk Management. 2015 Apr 2
• 3 citations
  Management of thrombocythemia
  Krisstina L. Gowin, Ruben A. Mesa> ;F1000research. 2014 Sep 29
• 10 citations
  The New Landscape of Therapy for Myelofibrosis
  Krisstina L. Gowin, Robyn M. Emanuel, Holly L. Geyer, Ruben A. Mesa> ;Current Hematologic Malignancy Reports. 2013 Oct 8
• 7 citations
  Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis.
  Krisstina L. Gowin, Ruben A. Mesa> ;Expert Opinion on Investigational Drugs. 2013 Nov 12
• 65 citations
  Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients
  Krisstina Gowin, Prakash Thapaliya, Jan Samuelson, Claire N. Harrison, Deepti Radia, Bjorn Andreasson, John Mascarenhas, Alessandro Rambaldi, Tiziano Barbui, Catherine...> ;Haematologica. 2012 Oct 1
• Join now to see all

Abstracts/Posters

• Integrative Medicine Modality Utilization and Impact on Quality of life in Cancer Patients
  Millstine, D and Gowin, K, ASCO survivorship symposium, 1/1/2016
• Limitation of fibrosis grade as diagnostic criteria for post polycythemia vera and essesntial thrombocytosis myelofibrosis
  Gowin KL, Verstovsek S, Gustad Daver N, Pemmaraju N, Valdez R, Kosieorek H, Dueck AC, Mesa RA, J Clin Oncol, 1/1/2015
• Interim Analysis of a Phase II Pilot Trial of Ruxolitinib combined with Danazol for Patients with Myelofibrosis Suffering from Anemia
  Gowin K, Dueck A, Mascarenhas J, Hoffman R, Nagi Reddy S, Reeder C, Camoriano J, Fauble V, Tibes R, Gano K, Ghurye V, Koenig P, Mesa R, 20th Congress of the European Hematology Association, Vienna, Austria, 1/1/2015
• Final Analysis of a Multicenter Pilot Phase 2 Study of Ruxolitinib and Danazol in Patients with Myelofibrosis
  Gowin K, Dueck A, Mascarenhas J, Hoffman R, Nagi Reddy S, Reeder C, Camoriano J, Fauble V, Tibes R, Gano K, Ghurye V, Koenig P, Mesa R, Blood, 1/1/2015
• Pegylated Interferon Alpha-2a in 75 Patients with Myeloproliferative Neoplasms: A Single Center Experience
  Gowin, K., Jain, T., Kosiorek, H.,Tibes, R., Camoriano, J., Palmer, J. and Mesa, R, Blood, 1/1/2015
• Poor Correlation between DIPSS and Passamonti Prognostic Risk Scores for Post Polycythemia and Essential Thrombocytosis Myelofibrosis
  Coakley, M., Gowin, K., Kosiorek, H., and Mesa, R, Blood, 1/1/2015
• Integrative Medicine Modality Utilization and Impact on Quality of life in Cancer Patients
  Gowin, K, Chon, T, and Millstine, D, SIO, 1/1/2015
• Interim analysis of a phase ii pilot trial of ruxolitinib combined with danazol for patients with primary myelofibrosis (mf), post essential thrombocythemia-myelofibro...
  Gowin KL, Dueck AC, Mascarenhas JO, Hoffman R, Reeder CB, Camoriano J, Gano K, Ghurye V, Reddy SN, Koenig P, Fauble V, Tibes R, Mesa R, Blood, 1/6/2014
• The clinical phenotype of patients with primary myelofibrosis, polycythemia vera, and essential thrombocytosis whom only manifest who grade 1 fibrosis
  Gowin KL, Dueck AC, Verstovsek S, Daver N, Pemmaraju N, Valdez R, Mesa RA, Blood, 1/6/2014
• A new prognostic model for response in myelofibrosis patients treated with jak2 inhibitors: a study from three US academic centers
  Kamal M, Boonstra PS, Weber AA, Perkins C, Gowin KL, Nguyen H, Mesa R, Gotlib JR, Talpaz M, Blood, 1/6/2014
• The hedgehog pathway as targetable vulnerability with 5-azacitidine in mds and aml
  Tibes R, Delman D, Hansen N, Gowin KL, Mesa R, Bogenberger JM, Blood, 1/6/2014
• Allogeneic transplant outcomes in mpn blast phase
  Gowin K, Cherington C, Slack J, Tibes R, Sproat L, Mesa R, Haematologica, 1/1/2014
• Patient Preference for Integrative Oncology Services: Living with Cancer 2014
  Millstine DM, Gowin K, Chon TY, Mayer AP, Bergstrom LR, 11th Annual Society of Integrative Medicine, 1/1/2014
• The hedgehog pathway as a targetable vulnerability with 5-azacitidine in MDS and AML
  Tibes R, Delman D, Hansen N, Gowin KL, Mesa R, Bogenberger JM, Blood, 1/1/2014
• Pegylated interferon alpha-2a in patients with myeloproliferative neoplasms (MPN): international experience in 115 cases
  Gowin K, Thapaliya P, Samuelson J, Harrison CN, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea CJ, Camoriano J, Gentry A, Kiladjian JJ, O'Connell CL, ..., Blood, 1/18/2011
• Patients with Polycythemia Vera and Essential Thrombocytosis have a higher risk of prior or concurrent tumors compared to patients with secondary thrombocytosis
  Gowin K, Piatek C, et al., Blood, 1/1/2010
• Join now to see all

Lectures

• Integrative Palliative Care 
  Mayo Clinic, Scottsdale, AZ - 1/1/2016
• Exercise in Cancer Care 
  Arizona State University, Tempe, AZ - 1/1/2015
• Movement as Medicine 
  Mayo Clinic Cancer Center, Scottsdale, AZ - 1/1/2015
• Profile of pomalidomide and its potential in the treatment of myelofibrosis 
  1/1/2015
• Limitations of fibrosis grade as diagnostic criteria for post polycythemia vera and essential thrombocytosis myelofibrosis 
  1/1/2015
• Ruxolitinib for the treatment of polycythemia vera 
  1/1/2015
• Management of thrombocythemia 
  1/29/2014
• Lymphadenopathy: Do we have B or P cells to blame? 
  Mayo Clinic Arizona, Phoenix, AZ - 1/1/2014
• Helping Children and Teens Cope with MPN in the Family 
  1/1/2014
• Recognizing the Different Stages of Your MPN: Understanding Why Your Doctor May Need to Adjust Your Treatment Over Time 
  1/1/2014
• The Role of Exercise, Meditation, and Nutrition to Cope with MPN 
  1/1/2014
• Progress in the Treatment of Myeloproliferative Neoplasms (MPN) 
  1/1/2014
• Overview of Myelofibrosis, Current Treatment Options and Quality of Life Concerns 
  1/1/2014
• Heavy Symptom Burden and Early Myelofibrosis in Polycythemia Vera and Essential Thrombocytosis 
  Phoenix, AZ - 1/1/2014
• The Cognitive Error Paradigm 
  1/1/2014
• The new landscape of therapy for myelofibrosis 
  1/1/2013
• Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis 
  1/1/2013
• Lessons on treating cancer: a caregiver's perspective 
  1/1/2013
• Experience with pegylated interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients 
  1/1/2012
• Essential Thrombocytosis 
  University of Southern California, Los Angeles, CA, 2010 - 1/1/2011
• A Rare Complication of Paracentesis 
  University of Southern California, Los Angeles, CA - 1/1/2009
• Join now to see all